Market News & Trends
Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial
Opthea Limited recently announced the last patient has been enrolled in the company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD),…
Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology
Novo Nordisk recently announced the completion and results regarding its Pioneer 9 and Pioneer 6 Phase 3a trials, both conducted with oral semaglutide, a once-daily…
CBT Pharmaceuticals & Zhejiang Bossan Pharmaceutical Enter Collaboration & License Agreement
CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) recently announced they have entered into a clinical collaboration and license agreement to develop their…
Dalton Pharma Services Enters Drug Development & Manufacturing Services Agreement
Dalton Pharma Services recently announce a drug development and manufacturing services agreement with ExCellThera Inc. This agreement provides ExCellThera access to Dalton’s state-of-the-art cGMP, Health…
Edge Therapeutics Enters Into Merger Agreement With PDS Biotechnology
Edge Therapeutics, Inc. and PDS Biotechnology Corporation recently announced their respective boards of directors have approved a definitive merger agreement. The merger is expected to…
Ajinomoto Bio-Pharma Services Introduces Bioconjugation Technology for ADC Manufacturing
Ajinomoto Bio-Pharma Services recently presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.
Evelo & Merck Enter Clinical Trial Collaboration
Evelo Biosciences, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination with KEYTRUDA (pembrolizumab).
Cambrex to Acquire Avista Pharma Solutions
Cambrex Corporation recently announced it has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
OSE Immunotherapeutics & Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial
OSE Immunotherapeutics SA recently announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved…
BrainStorm Cell Therapeutics Announces Submission of IND
BrainStorm Cell Therapeutics Inc. recently announced that it has submitted an Investigational New Drug (IND) application with the US FDA to initiate a Phase 2…
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Clinical Trial
Tenax Therapeutics, Inc. recently announced that Stanford University School of Medicine has been activated as the first clinical research site for the company’s Phase 2…
Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials
Adial Pharmaceuticals, Inc. and Crown CRO recently announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use…
New Phase 1 Zika Vaccine Trial Meets Primary Endpoint
Emergent BioSolutions Inc. and Valneva SE (VLA) recently announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The…
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA
Synthetic Biologics, Inc. recently announced it has successfully completed an End-of-Phase 2 meeting with the US FDA to discuss development of SYN-004 (ribaxamase) for the…
Roivant Sciences & iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic; Deal Worth $667.5 Milllion
Roivant Sciences and iNtRON Biotechnology recently announced they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of $667.5 million inclusive of milestone payments, with royalties on net sales in the low double digits.
CordenPharma Announces Successful SafeBridge Recertification
CordenPharma Colorado has successfully completed the Potent Compound Recertification Audit by SafeBridge Consultants. Certification has been maintained since first awarded in 2013.
Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline
Cadent Therapeutics recently announced it has raised $40 million in a Series B financing. In addition, the company has appointed Bob (Ibrahim) Dagher, MD, as…
Provectus Biopharmaceuticals Provides Drug Development Update
Provectus recently provided an update on the company’s small molecule clinical development program for its investigational immuno-dermatology drug PH-10 for the treatments of psoriasis and…
Synteract Acquires Pediatric CRO to Further Strengthen its Pediatric Center of Development
Synteract has acquired KinderPharm, a specialty pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. Like Synteract, KinderPharm has extensive experience in…
Fujifilm Announces Research Results for Novel Liposome Drug Candidate
FUJIFILM Corporation recently announced the drug release mechanism of continuous action in tumors for the anti-cancer agent FF-10832, currently undergoing Phase I clinical trials in…
